Professional Documents
Culture Documents
Outline
BSci106:
MICROBIOLOGY and • Introduction • Drug Resistance
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
• Chemotherapy is the use of any chemical (drug) to • Drugs used to treat bacterial diseases are called
treat any disease or condition. antibacterial agents; those used to treat fungal diseases,
antifungal agents; those used to treat protozoal diseases,
• A chemotherapeutic agent is any drug used to treat antiprotozoal agents; and those used to treat viral
diseases, antiviral agents.
any condition or disease.
• An antibiotic is a substance produced by a microorganism
• An antimicrobial agent is any chemical (drug) used to that kills or inhibits the growth of other microorganisms.
treat an infectious disease, either by inhibiting or by
• Antibiotics that have been chemically modified to kill a
killing pathogens in vivo. Some antimicrobial agents are
wider variety of pathogens or reduce side effects are
antibiotics. called semisynthetic antibiotics; examples include
semisynthetic penicillins, such as ampicillin and
carbenicillin.
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
1
3/8/2023
• The five most common mechanisms of action of • Bacteriostatic drugs inhibit growth of bacteria, whereas
antimicrobial agents are bactericidal drugs kill bacteria.
– Inhibition of cell wall synthesis • Sulfonamide drugs inhibit production of folic acid (a
vitamin) in those bacteria that require p-aminobenzoic acid
– Damage to cell membranes to synthesize folic acid; without folic acid, bacteria cannot
produce certain essential proteins and die.
– Inhibition of nucleic acid synthesis (either DNA
or RNA synthesis) – Sulfa drugs are competitive inhibitors; they are
bacteriostatic.
– Inhibition of protein synthesis
• In most Gram-positive bacteria, penicillin interferes with
– Inhibition of enzyme activity the synthesis and cross-link ing of peptidoglycan, a
component of cell walls. By inhibiting cell wall synthesis,
penicillin destroys the bacteria.
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
2
3/8/2023
• Most antifungal agents work in one of three ways: • Antiprotozoal agents are usually toxic to the host.
– By binding with cell membrane sterols (e.g., • Antiprotozoal agents work by
nystatin and amphotericin B)
– I nter f er ing with D NA and RNA sy nt he sis (e. g . ,
– B y in terf er ing w it h s te ro l sy nth esi s (e. g.,
clotrimazole and miconazole) chloroquine, pentamidine, and quinacrine)
– By blocking mitosis or nucleic acid synthesis – Interfering with protozoal metabolism (e.g.,
(e.g., griseofulvin and 5-flucytosine) metronidazole)
• Antifungal agents and antiprotozoal agents tend to
be more toxic to the patient because, like the
infected human, they are eukaryotic organisms.
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
• Antiviral agents are the newest weapons in • Superbugs are microbes (mainly bacteria) that have
antimicrobial methodology. become resistant to one or more antimicrobial
agents. Infections caused by superbugs are difficult
• Difficult to develop these agents because viruses are to treat.
produced within host cells.
• Bacterial superbugs include methicillin-resistant
• Some drugs have been developed that are effective Staphylococcus aureus (MRSA); vancomycin-
in certain viral infections, but not others; they work resistant Enterococcus spp. (VRE); multidrug-
by inhibiting viral replication within cells. resistant Mycobacterium tuberculosis (MDRTB);
multidrug-resistant strains of Acinetobacter,
• “ C o c k t a i l s ” ( s e v e r a l a nt i v i r a l d r u g s t h a t a r e Burkholderia, E. coli, Klebsiella, Pseudomonas,
administered simultaneously) are being used to Stenotrophomonas, Salmonella, Shigella, and N.
treat HIV infection. gonorrhoeae; β-lactamase-producing strains of
Streptococcus pneumoniae and Haemophilus
influenzae; carbapenemase-producing Klebsiella
pneumoniae.
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
3
3/8/2023
Drug Resistance:
How Bacteria Become Resistant to Drugs Drug Resistance: How Bacteria Become
(cont.) Resistant to Drugs (cont.)
• To enter a bacterial cell, a drug must be able to pass through • Bacteria can also become resistant to drugs by developing
the cell wall and cell membrane; chromosomal mutations the ability to produce multidrug-resistance (MDR) pumps
may alter the structure of the cell membrane, thus (also known as MDR transporters or efflux pumps).
preventing the drug from entering the cell; this results in – An MDR pump enables the cell to pump drugs out
drug resistance. before they can damage or kill the cell.
• Bacteria can develop the ability to produce an enzyme that • Summary: Bacteria can acquire resistance to antimicrobial
destroys or inactivates a drug. agents by chromosomal mutation or by the acquisition of
– Many bacteria have become resistant to penicillin new genes by transduction, transformation, and, most
because they have acquired the gene for penicillinase commonly, by conjugation.
production during conjugation.
• A plasmid that contains multiple genes for drug resistance is
known as a resistance factor (R-factor).
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
4
3/8/2023
Empiric Therapy:
Empiric Therapy Factors to Be Considered
• Empiric therapy is when drug therapy is initiated • If pathogen identity is • Is the drug the hospital
before laboratory results are available (i.e., before known, use the “pocket formulary?
the pathogen is identified and/or before chart” of antimicrobial
susceptibility test results are available). susceptibility test data from • Site of the infection?
the past year. • What other medication(s)
– Empiric therapy is sometimes necessary to save
a patient’s life. • Is the patient allergic to any is the patient taking?
antimicrobial agents? • What other medical
– Clinicians make an “educated guess” based on
past experience with the type of infectious • What is the age of the problems does the patient
disease and the most effective drugs. patient? have?
• Clinicians must take a numbe r of fac tors into • Is the patient pregnant? • Is the patient leukopenic or
consideration before prescribing antimicrobial agents. immunocompromised?
• Inpatient or outpatient?
• What is the cost of the
drug(s)?
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
Copyright © 2015 Wolters Kluwer • All Rights Reserved Copyright © 2015 Wolters Kluwer • All Rights Reserved
A. Indigenous microbiota of
a patient before antibiotic
therapy (S, susceptible; R,
resistant).
B. After antibiotic therapy
has been initiated.
C. Resistant organisms
multiply and become the
predominant organisms.